Article Text
PDF
Statistics from Altmetric.com
Q In black patients with New York Heart Association (NYHA) class III or IV heart failure (HF) with dilated ventricles, is a fixed dose of isosorbide dinitrate plus hydralazine (ID+H) better than placebo?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Cardiology ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial (African-American Heart Failure Trial [A-HeFT]).
Allocation:
concealed.*
Blinding:
blinded (clinicians, patients, data collectors, outcome assessors, monitoring committee, and statisticians).*
Follow up period:
18 months.
Setting:
161 centres in the US.
Patients:
1050 adults (mean age 57 y, 60% men) self identified as black who had NYHA class III or IV HF for ⩾3 months, had left ventricular dysfunction in the preceding 6 months, and were receiving standard HF therapy. Exclusion criteria included acute MI, stroke, cardiac surgery, or …
Linked Articles
- Glossary